Virus-Like Particle display for long-lasting vaccine protection
AdaptVac aims to development highly effective and long-lasting therapeutic and prophylactic vaccines within oncology, infectious diseases and immunological disorders.
​
AdaptVac's out-licensed ABNCoV2 COVID-19 vaccine, has met its primary objective in Phase 3, demonstrating non-inferiority to the Comirnaty® mRNA-vaccine. Additionally, safety data from 4,205 individuals followed up for 6 months post vaccination showed ABNCoV2 to be well-tolerated with no serious adverse events being reported, as well as excellent 12 month durable antibody responses in PhII.
​
Our second out-licensed clinical program, a HER2+ cVLP therapeutic breast cancer vaccine, has initiated a Ph1 study in Austria.
​
Our cVLP Nipah virus vaccine has achieved Proof-of-Concept, and is currently being transferred to Northway Biotech for GMP manufacture in preparation for a Phase 1/2a clinical study with planned initiation start 2027.
​
​
Phase 3 validated
Tag/Catcher cVLP display platform
AdaptVac's iso-peptide display platform utilises our proprietary MoonCatcher/Tag pair.
​
Furthermore, the cVLP is based on Tag or Catcher fused Bacteriophage AP205 capsid protein, which spontaneously forms a capsid Virus-Like Particle during production in E.coli.
​
MoonCatcher and AP205 have now been through Phase 3 clinical testing in our ABNCoV2 COVID-19 vaccine program. Demonstrating safety and regulatory acceptance for our platform.